NCT06907771

Brief Summary

Ovarian cancer is the 8th leading cause of cancer-related death in women. Its prognosis is poor, with diagnosis often made at an advanced stage. Patient management has evolved in recent years with more radical surgeries and the introduction of maintenance treatment following neoadjuvant chemotherapy.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
130

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Apr 2024

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 22, 2024

Completed
11 months until next milestone

First Submitted

Initial submission to the registry

March 26, 2025

Completed
7 days until next milestone

First Posted

Study publicly available on registry

April 2, 2025

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 22, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 22, 2025

Completed
Last Updated

April 2, 2025

Status Verified

March 1, 2025

Enrollment Period

1.7 years

First QC Date

March 26, 2025

Last Update Submit

March 26, 2025

Conditions

Ovarian Cancer

Keywords

Ovarian cancer

Outcome Measures

Primary Outcomes (1)

  • Study of progression-free survival at 36 months

    At 36 months

Eligibility Criteria

Age18 Years+
Sexfemale
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Adult patient (≥18 years old) having undergone primary or interval cytoreductive surgery

You may qualify if:

  • Adult patient (≥18 years old)
  • Operated on at the HUS between January 1, 2010 and December 31, 2022
  • Having undergone primary or interval cytoreductive surgery
  • Suffering from stage FIGO IIIC or IV high-grade serous carcinoma of ovarian origin

You may not qualify if:

  • Patiente ayant exprimé son opposition à la réutilisation de ses données à des fins de recherches scientifiques.
  • Autres types histologiques de cancer de l'ovaire
  • Stades de la maladie FIGO I, II, IIIA et IIIC
  • Chirurgie de clôture.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Service de Gynécologique et d'Obstétrique - CHU de Strasbourg - France

Strasbourg, France

RECRUITING

MeSH Terms

Conditions

Ovarian Neoplasms

Condition Hierarchy (Ancestors)

Endocrine Gland NeoplasmsNeoplasms by SiteNeoplasmsOvarian DiseasesAdnexal DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital Neoplasms, FemaleUrogenital NeoplasmsGenital DiseasesEndocrine System DiseasesGonadal Disorders

Central Study Contacts

Lise LECOINTRE, MD

CONTACT

33 3 88 12 75 10lise.lecointre@chu-strasbourg.fr

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 26, 2025

First Posted

April 2, 2025

Study Start

April 22, 2024

Primary Completion

December 22, 2025

Study Completion

December 22, 2025

Last Updated

April 2, 2025

Record last verified: 2025-03

Locations

FR(1)